Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

Will Resubmit With New Data from Ongoing Studies

CAMBRIDGE, Mass., March 19 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) today announced the withdrawal of the European application to extend the Evoltra(R) (clofarabine) product label to include the treatment of elderly patients with acute myeloid leukemia (AML). This application and the data on which it was based were filed by Bioenvision, Ltd. before the company was acquired by Genzyme last year.

In a letter to the European Medicines Agency (EMEA) on behalf of Bioenvision, Genzyme states that the withdrawal is based on the EMEA's Committee for Medicinal Products for Human Use (CHMP) assessment that the data from the BIOV121 study are not sufficient to support a recommendation for market approval at this time. Bioenvision is now a wholly-owned subsidiary of Genzyme.

"As we expected, the filing that Bioenvision submitted to the EMEA was not sufficient to support approval in adult AML and our subsequent conversations with the CHMP have confirmed this assessment," stated Mark J. Enyedy, president of Genzyme Oncology, a business unit of Genzyme Corp. "We have engaged in a positive dialogue with the Rapporteurs regarding the requirements for approval and will develop a new submission to include data from one or more ongoing clinical studies of clofarabine in this patient population for submission possibly as early as the fourth quarter of this year."

In the United States, Genzyme has completed enrollment for a pivotal study in previously untreated, older adult patients with AML who are unlikely to benefit from standard intensive induction chemotherapy. Data from this study, known as CLASSIC II, are expected to provide substantial evidence for expa
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... NY (PRWEB) June 18, 2013 In ... and sustainability, the Consulate General of Switzerland in New ... boat, Switzerland’s MS Tûranor PlanetSolar , to Manhattan. ... of its DeepWater Expedition 2013 tour with scientists on ... by Capitain Gérard d’Aboville, runs exclusively on energy from ...
(Date:6/18/2013)... Demanding industrial and environmental conditions are no ... and Glass Ball Lenses, now available in an extensive ... , of Philadelphia , PA. , Optical Ball Lenses ... beams without the need for direct physical contact. That’s ... mohs) make it the ideal choice for fiber-optic applications ...
(Date:6/18/2013)... AZ (PRWEB) June 18, 2013 Nasseo, ... 2013 Innovation Challenge Winner out of hundreds of applicants ... its spring Arizona Innovation Challenge . The Arizona ... country for a technology commercialization challenge, granting a financial ... most promising technology ventures. Nasseo’s state of the art ...
(Date:6/18/2013)... ATLANTA , June 18, 2013  regulated information ... Jeff Klauk today announced the launch of ... their loved ones. The Pledge ... take a stand and make a personal commitment to ... with their health care team and additional partial-onset seizure ...
Breaking Biology Technology:Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6
... 31 China Agro-Technology,Holdings Ltd ("CAT") today announced that ... Executive Officer, replacing interim CEO Harry,He, effective as of ... York., CAT is a leading agro-biotechnology company listed ... company reported total audited revenues of,US$37 million in fiscal ...
... DIEGO, Jan. 31 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI, ... infectious,diseases, will add a 600mg celgosivir combination therapy ... study in hepatitis C virus,("HCV") treatment-naive patients. The ... and Institutional Review Board (IRB) approvals. The,purpose of ...
... Research Initiatives in Search of a Cure and Therapies ... ... 31 The Christopher and Dana,Reeve Foundation (CDRF), which is dedicated ... quality of life for people,living with paralysis through grants, information and ...
Cached Biology Technology:China Agro-Technology Appoints New CEO 2China Agro-Technology Appoints New CEO 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 4MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 5MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 6Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 2Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 3
(Date:6/19/2013)... world-leading provider of scientific, technical and medical information products ... a new open access journal, GeoResJ . ... earth and planetary science journals portfolio has its first ... a forum for rapid publication of top research within ... co-edited by six Executive Editors, each covering a different ...
(Date:6/18/2013)... not a hacker lab. At Brandeis University, sophisticated ... are helping scientists understand the complex interplay between ... the virus, outer "shell" critical for replication. ... what we are finding will help researchers alter ... post-doctoral fellow Jason Perlmutter, first author of the ...
(Date:6/18/2013)... 18, 2013: The Association for Molecular Pathology is proud ... Societies for Experimental Biology (FASEB) on July 1, 2013. ... June 3, 2013. , The 26 constituent societies ... a common vision for the advancement of research and ... translational research is more important now than ever," said ...
Breaking Biology News(10 mins):Computer modeling technique goes viral at Brandeis 2
... have discovered a new source of stems cells and ... vessel, nerve and liver cells in the laboratory. The ... cells from the amniotic fluid that surrounds developing embryos ... is that these cells will provide a valuable resource ...
... Immune cells that are the body’s front-line defense don’t ... on their outside skins and rouse them to action, ... Michigan scientists describe their findings that bacteria can barge ... immune response. , The study, published online ahead ...
... ocean circulation and sea levels in the centuries to come? ... zones in the oceans on the rise? Can aquaculture be ... the collapse of coastal fisheries? , Most importantly, what can ... of the news media are invited to join leading international ...
Cached Biology News:Scientists discover new, readily available source of stem cells 2Scientists discover new, readily available source of stem cells 3Microbes start immune response by sneaking inside cells 2Are we killing the world's oceans? 2
Anti-TWIK-1 Immunogen: Purified peptide from amino acids 53-69 of human TWIK-1 (Accession number O00180)....
Monoclonal 8C2.1 is specific for Bunyavirus G1 as tested by neutralization, immunoprecipitation and immunobinding assays....
BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
...
Biology Products: